Related Experiment Video
Updated: Feb 24, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
From Pulmonary Tuberculosis to Antineutrophil Cytoplasmic Antibody (ANCA) Seroconversion: A Case of Rapidly
Omar A AlShammari1,2, Ibrahim Abuqurayn1, Iffat Kiran1
1Nephrology, King Fahad Medical City, Riyadh, SAU.
Abstract:
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a small-vessel inflammatory disorder that can lead to rapidly progressive glomerulonephritis. Although tuberculosis has been linked to ANCA positivity, the development of biopsy-confirmed immune-mediated kidney disease during anti-tuberculosis therapy is rare. Herein, we describe a rare presentation of delayed ANCA seroconversion associated with rapidly progressive glomerulonephritis in a patient undergoing pulmonary tuberculosis treatment. We report the clinical course, laboratory findings, histopathology, and management of the case. A 49-year-old man with pulmonary tuberculosis initially presented with mild renal impairment and negative autoimmune serology and was treated with standard anti-tuberculosis therapy. Several months later, he developed recurrent hemoptysis accompanied by rapidly worsening kidney function and active urinary sediment. Repeat serological evaluation demonstrated a new cytoplasmic staining pattern on indirect immunofluorescence for antineutrophil cytoplasmic antibodies, consistent with proteinase 3 antibody positivity on antigen-specific immunoassay. Renal biopsy revealed pauci-immune crescentic glomerulonephritis, confirming ANCA-associated rapidly progressive glomerulonephritis. Following a multidisciplinary discussion, immunosuppressive therapy was initiated, and anti-tuberculosis treatment was continued. Despite the therapy, the patient remained dialysis dependent. In summary, delayed ANCA seroconversion may occur during anti-tuberculosis therapy and may be associated with severe immune-mediated renal disease. Kidney biopsy is essential when unexplained kidney deterioration develops during treatment. In selected patients with severe organ involvement, immunosuppressive therapy may be required despite active infection, following careful multidisciplinary evaluation.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Acute Kidney Injury II: Pathophysiology

